[go: up one dir, main page]

MA37693A1 - Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application - Google Patents

Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application

Info

Publication number
MA37693A1
MA37693A1 MA37693A MA37693A MA37693A1 MA 37693 A1 MA37693 A1 MA 37693A1 MA 37693 A MA37693 A MA 37693A MA 37693 A MA37693 A MA 37693A MA 37693 A1 MA37693 A1 MA 37693A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
improved
powderiness
manufacture
application
Prior art date
Application number
MA37693A
Other languages
Arabic (ar)
English (en)
Other versions
MA37693B1 (fr
Inventor
Alexandre Vasilievich Ivachtchenko
Alexandre Viktorovich Demin
Original Assignee
Alexandre Vasilievich Ivachtchenko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49446598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37693(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexandre Vasilievich Ivachtchenko filed Critical Alexandre Vasilievich Ivachtchenko
Publication of MA37693A1 publication Critical patent/MA37693A1/fr
Publication of MA37693B1 publication Critical patent/MA37693B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte au domaine de la pharmaceutique et notamment des compositions pharmaceutiques solides comprenant du 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol ou un sel pharmaceutiquement acceptable de celui-ci, une substance de glissement et une matière de charge ; l'invention concerne également des procédé de production de la composition pharmaceutique, des agents médicamenteux de suppression du système immunitaire et de traitement de la sclérose diffuse. Le 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol consiste en un immuno-modulateur qui entraîne une redistribution des lymphocytes du flux sanguin dans les tissus lymphatiques secondaires, entraînant ainsi une immunosuppression. L'invention assure une répartition uniforme du composant actif dans la composition solide, une grande stabilité et une meilleure pulvérulence de la composition pharmaceutique. Grâce à cette meilleure pulvérulence, la composition de la présente invention peut être utilisée dans un équipement automatique
MA37693A 2012-07-11 2014-12-24 Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application MA37693B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012129101/15A RU2496486C1 (ru) 2012-07-11 2012-07-11 Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
PCT/RU2013/000572 WO2014011083A2 (fr) 2012-07-11 2013-07-05 Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application

Publications (2)

Publication Number Publication Date
MA37693A1 true MA37693A1 (fr) 2016-06-30
MA37693B1 MA37693B1 (fr) 2017-01-31

Family

ID=49446598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37693A MA37693B1 (fr) 2012-07-11 2014-12-24 Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application

Country Status (22)

Country Link
US (1) US9370576B2 (fr)
EP (1) EP2873416B1 (fr)
JP (1) JP6093015B2 (fr)
KR (1) KR20150036228A (fr)
CN (1) CN104487063B (fr)
AP (1) AP2014008171A0 (fr)
BR (1) BR112015000544A2 (fr)
CL (1) CL2015000052A1 (fr)
CO (1) CO7310521A2 (fr)
EA (1) EA027712B1 (fr)
GE (1) GEP201606571B (fr)
IL (1) IL236562A0 (fr)
IN (1) IN2015DN00130A (fr)
MA (1) MA37693B1 (fr)
MX (1) MX2015000467A (fr)
PE (1) PE20150632A1 (fr)
RU (1) RU2496486C1 (fr)
SG (1) SG11201500178QA (fr)
TN (1) TN2015000006A1 (fr)
UA (1) UA113216C2 (fr)
WO (1) WO2014011083A2 (fr)
ZA (1) ZA201409481B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2943257A4 (fr) 2013-01-10 2016-08-17 Edh Us Llc Mesure de vitesse de rotation de balle
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
EP3813822A4 (fr) * 2018-06-27 2022-03-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions pharmaceutiques solides d'administration par voie orale comprenant du tériflunomide

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
DE69633613T2 (de) 1995-12-28 2006-02-09 Mitsubishi Pharma Corp. 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-diol enthaltendes Arzneimittel zur topischen Anwendung zur Behandlung von Erkrankungen,die durch eine Störung des Immunsystems hervorgerufen werden
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
RU2358717C2 (ru) 2002-05-16 2009-06-20 Новартис Аг Применение средств, связывающих edg-рецептор, в лечении ракового заболевания
CA2521325C (fr) * 2003-04-08 2010-09-14 Novartis Ag Compositions pharmaceutiques solides comprenant un agoniste des recepteurs de la s1p et un alcool de sucre
AU2004271804B2 (en) * 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
US20080096972A1 (en) 2004-07-30 2008-04-24 Thitiwan Buranachokpaisan Compound formulations of 2-amino-1, 3-propanediol compounds
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
MXPA05008573A (es) 2005-08-12 2007-02-12 Leopoldo Espinosa Abdala Composicion de isoflavonas para tratamiento de los sintomas y trastornos fisiologicos de la menopausia.
KR101884047B1 (ko) * 2006-09-26 2018-07-31 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
EP1923058A1 (fr) * 2006-09-26 2008-05-21 Novartis AG Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P
PL2465492T3 (pl) * 2007-10-12 2015-11-30 Novartis Ag Mieszaniny zawierające modulatory receptora 1-fosforanu sfingozyny (S1P)
CA2797042A1 (fr) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod sous la forme de solution solide
US20130102683A1 (en) * 2010-04-22 2013-04-25 Ratiopharm Gmbh Melt-granulated fingolimod

Also Published As

Publication number Publication date
CN104487063A (zh) 2015-04-01
CL2015000052A1 (es) 2015-09-04
MX2015000467A (es) 2015-06-05
MA37693B1 (fr) 2017-01-31
WO2014011083A3 (fr) 2014-03-06
BR112015000544A2 (pt) 2017-10-24
IL236562A0 (en) 2015-02-26
RU2496486C1 (ru) 2013-10-27
EP2873416B1 (fr) 2017-04-26
PE20150632A1 (es) 2015-05-20
EP2873416A2 (fr) 2015-05-20
WO2014011083A2 (fr) 2014-01-16
EP2873416A4 (fr) 2016-03-16
IN2015DN00130A (fr) 2015-05-29
EA201500096A1 (ru) 2015-05-29
JP2015522068A (ja) 2015-08-03
GEP201606571B (en) 2016-11-10
UA113216C2 (xx) 2016-12-26
CN104487063B (zh) 2017-05-10
AP2014008171A0 (en) 2014-12-31
SG11201500178QA (en) 2015-03-30
TN2015000006A1 (en) 2016-06-29
CO7310521A2 (es) 2015-06-30
US9370576B2 (en) 2016-06-21
KR20150036228A (ko) 2015-04-07
ZA201409481B (en) 2016-02-24
EA027712B1 (ru) 2017-08-31
JP6093015B2 (ja) 2017-03-08
US20150335754A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
MY202371A (en) Hexone glucokinase inhibitor and use thereof
CY1124878T1 (el) Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης
EP4403579A3 (fr) Formulation pour anticorps anti-alpha4bêta7
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
MY168791A (en) Carbamate compounds and of making and using same
JO3784B1 (ar) الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان
MX389751B (es) Composición farmacéutica y administraciones de la misma.
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
MY183471A (en) Formulation for anti-?4?7 antibody
WO2017180917A3 (fr) Compositions lipidiques et leurs utilisations pour l'administration intratumorale de polynucléotides
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
BR112014008552A2 (pt) r(+)-n-metil-propargilaminoindano
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
BR112012017691A2 (pt) nova composição
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
BR112014011609A2 (pt) material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco
EA201590193A1 (ru) Препараты лаквинимода без подщелачивающего агента
MA37693A1 (fr) Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
EP3399040A4 (fr) Procédé de préparation d'une protéine de capside de circovirus porcin de type 2 et composition pharmaceutique la contenant
SG11202108280RA (en) Concentrated liquid pharmaceutical formulations of furosemide and methods of administering the same
WO2016195194A3 (fr) Nouveaux antagonistes de tlr2
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.
TN2013000442A1 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY